Last reviewed 2026-04-20 · How we verify

Optional Prednisone

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue (asthenia, lethargy, malaise)
• Leukocytes (total WBC)
• Lymphopenia
• Hemoglobin
• Platelets
• Neutrophils/granulocytes (ANC/AGC)
• ALT, SGPT (serum glutamic pyruvic transaminase)
• Nausea
• Cough
• AST, SGOT(serum glutamic oxaloacetic transaminase)
• Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)
• Albumin, serum-low (hypoalbuminemia)

Key clinical trials

• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (PHASE2)
• Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
• Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
• Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS (PHASE1, PHASE2)
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NA)
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Optional Prednisone CI brief — competitive landscape report
• Optional Prednisone updates RSS · CI watch RSS
• Prevail Therapeutics portfolio CI